Abstract
Alterations in microRNA (miRNA) expression in postmortem brain tissue or peripheral blood have been linked to schizophrenia. Cerebrospinal fluid might provide an in vivo biomarker more directly reflecting functional changes in the brain. The goals of this study were to determine the feasibility of detecting miRNAs in cerebrospinal fluid and to compare miRNA levels in cerebrospinal fluid versus blood. Four healthy volunteers and four patients with psychotic disorders underwent a lumbar puncture and a blood draw. Expression of 378 validated miRNAs was assessed from each biofluid type for each subject using microarray technology. Five miRNAs were chosen for validation with quantitative polymerase chain reaction. A substantial number of miRNAs (n = 95) were exclusively or predominately detected in cerebrospinal fluid (CSF). Levels of 35 miRNAs detected in both CSF and blood samples in all subjects were poorly correlated. The investigation of miRNAs in CSF can help advance the understanding of psychiatric diseases and particularly schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
References
Baraniskin A, Kuhnhenn J, Schlegel U et al (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117:3140–3146
Baraniskin A, Kuhnhenn J, Schlegel U (2012) Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol 14(1):29–33, PubMed PMID:21937590; PubMed Central PMCID:PMC3245991
Beveridge NJ, Tooney PA, Carroll AP et al (2008) Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 17:1156–1168
Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ (2010) Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 15:1176–1189
Cogswell JP, Ward J, Taylor IA et al (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. Journal of Alzheimer's disease JAD 14:27–41
Gardiner E, Beveridge NJ, Wu JQ et al (2011) Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry. doi:10.1038/mp.2011.78
Ghidoni R, Benussi L, Paterlini A (2011) Cerebrospinal fluid biomarkers for Alzheimer’s disease: the present and the future. Neurodegener Dis 8(6):413–420, Review. PubMed PMID:21709402
Hunsberger JG, Austin DR, Chen G, Manji HK (2009) MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med 11:173–182
Kim J, Krichevsky A, Grad Y (2004) Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci USA 101:360–365
Kim AH, Reimers M, Maher B et al (2010) MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 124:183–191
Kranaster L, Koethe D, Hoyer C, Meyer-Lindenberg A, Leweke FM (2011) Cerebrospinal fluid diagnostics in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 261(7):529–530
Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T (2002) Identification of tissue-specific microRNAs from mouse. Current biology CB 12:735–739
Latronico MV, Condorelli G (2009) MicroRNAs and cardiac pathology. Nature reviews Cardiology 6:419–429
Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838
McCullumsmith RE, Meador-Woodruff JH (2011) Novel approaches to the study of postmortem brain in psychiatric illness: old limitations and new challenges. Biol Psychiatry 69:127–133
Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E, Akbarian S (2009) Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 65:1006–1014
Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM (2011) Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry 69:188–193
Olsen L, Klausen M, Helboe L, Nielsen FC, Werge T (2009) MicroRNAs show mutually exclusive expression patterns in the brain of adult male rats. PLoS One 4:e7225
Perkins DO, Jeffries CD, Jarskog LF et al (2007) MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8:R27
Ramachandran S, Palanisamy V (2011) Horizontal transfer of RNAs: exosomes as mediators of intercellular communication. Wiley Interdiscip Rev RNA. doi:10.1002/wrna.115
Ripke S, Sanders AR, Kendler KS et al (2011) Genome-wide association study identifies five new schizophrenia loci. Nat Genet 43(10):969–976. doi:10.1038/ng.940
Rong H, Liu TB, Yang KJ et al (2011) MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 45:92–95
Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ (2011) Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 69:180–187
Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476
Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. American journal of medical genetics Part B, Neuropsychiatric genetics 141B:261–268
Zhu Y, Kalbfleisch T, Brennan MD, Li Y (2009) A microRNA gene is hosted in an intron of a schizophrenia-susceptibility gene. Schizophr Res 109:86–89
Acknowledgments
Funding of this study was provided by the National Institute of Health grants: R01MH079800 (Malhotra), P50 MH080173-04 (Malhotra), M01RR018535 (Feinstein Institute for Medical Research-General Clinical Research Center), and UL1 RR025750 (Albert Einstein College of Medicine-CTSA). These funding agencies did not play a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. We wish to thank Jason Gentile, Brian J. Cantley RN, Christopher Morell, M.A, Nisha Chitkara PhD and Steve M. Ventura B.S for their help with study implementation.
Financial Disclosures
Drs. Gallego has nothing to disclose. Dr. Gordon has received research support (without direct compensation) from Eli Lilly and Forest Research Institute and has received honoraria for speaking from Novartis and fees for consulting from Accera, Eli Lilly, and GE Healthcare. Ms. Klaycomb and Bhatt are employees of Asuragen, Inc. Dr. Lencz has received consulting fees from Eli Lilly on an unrelated project. Dr. Malhotra has received grant/research support from Eli Lilly; has received honoraria for speaking from Merck, Sunovion Pharmaceuticals, Inc., and Shire; has served as a consultant for Eli Lilly and PGx Health; and has been on a scientific advisory board for Genomind.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Lencz and Dr. Malhotra contributed equally to this work.
This work was presented as a poster at the International Congress on Schizophrenia Research, April 2011.
Electronic Supplementary Materials
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 20 kb)
Rights and permissions
About this article
Cite this article
Gallego, J.A., Gordon, M.L., Claycomb, K. et al. In Vivo MicroRNA Detection and Quantitation in Cerebrospinal Fluid. J Mol Neurosci 47, 243–248 (2012). https://doi.org/10.1007/s12031-012-9731-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-012-9731-7